-
So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2021 Financial Results
Source: Nasdaq GlobeNewswire / 25 Mar 2022 04:30:00 America/New_York
BEIJING, March 25, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021.
Fourth Quarter 2021 Financial Highlights
- Total revenues were RMB449.5 million (US$70.5 million1), an increase of 5.9% from RMB424.6 million in the same period of 2020, in line with our previous guidance.
- Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.
- Non-GAAP net income attributable to So-Young International Inc.2 was RMB62.9 million (US$9.9 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB63.1 million in the fourth quarter of 2020.
Fourth Quarter 2021 Operational Highlights
- Average mobile MAUs were 7.4 million, compared with 8.9 million in the fourth quarter of 2020.
- Number of paying medical service providers on So-Young’s platform were 5,327, an increase of 12.2% from 4,746 in the fourth quarter of 2020.
- Number of medical service providers subscribing to information services on So-Young’s platform were 2,085, compared with 2,239 in the fourth quarter of 2020.
- Total number of users purchasing reservation services were 159.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB532.7 million.
Fiscal Year 2021 Financial Highlights
- Total revenues were RMB1,692.5 million (US$265.6 million) in the full year 2021, an increase of 30.7% from RMB1,295.0 million in the prior year.
- Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million) in the full year 2021, compared with a net income attributable to So-Young International Inc. of RMB5.8 million in the prior year.
- Non-GAAP net income attributable to So-Young International Inc. was RMB139.5 million (US$21.9 million) in the full year 2021, an increase of 42.4% from RMB98.0 million in the prior year.
Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “We achieved 30.7% revenue growth in 2021 with total revenues at RMB1.7 billion despite the weaker-than-normal consumer sentiment as a result of the COVID-19 pandemic. We continuously strengthened operating management ability and branding digital support for medical service providers on our platform to improve their acquisition efficiency and customer experience. As a result, the number of paying medical service providers on our platform were 6,634 in 2021, up 19.1% from 5,570 year-over-year. The average mobile MAUs reached 8.5 million in 2021, up 18.7% year-over-year.”
Mr. Jin continued, “In 2021, we were working to reinforce the trust with consumers, meeting medical and aesthetic consumer demand from the different levels to make efficient decisions. On the business side, we solidified our competitive advantage and completed the acquisition of Wuhan Miracle to create a competitive moat on non-surgical side. Stepping into 2022, we are committed to local aesthetic services to reaffirm our leadership position and building aesthetic supply chain ecosystem to ensure the management and control of product authenticity and supervision for customers.”
Mr. Min Yu, “We’re pleased to conclude 2021 with a solid revenue growth, which was very encouraging. Looking ahead, while exploring new business, we will maintain a healthy and sustainable revenue growth and earning in the long term as we continuously improve our operating efficiency and effectively control cost.”
Fourth Quarter 2021 Financial Results
Revenues
Total revenues were RMB449.5 million (US$70.5 million), an increase of 5.9% from RMB424.6 million in the same period of 2020. The increase was primarily due to the consolidated revenues of RMB63.8 million (US$10.0 million) in the fourth quarter of 2021 from Wuhan Miracle Laser Systems, Inc. (“Wuhan Miracle”), which was acquired on July 23, 2021.
- Information services and other revenues were RMB344.3 million (US$54.0 million), an increase of 2.5% from RMB335.9 million in the same period of 2020. The increase was primarily due to an increase in average revenue per paying medical service provider.
- Reservation services revenues were RMB41.4 million (US$6.5 million), a decrease of 53.4% from RMB88.7 million in the same period of 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.
- Sales of equipment and maintenance services revenues were RMB63.8 million (US$10.0 million), from Wuhan Miracle, our newly acquired subsidiary.
Cost of Revenues
Cost of revenues were RMB127.1 million (US$19.9 million), an increase of 99.8% from RMB63.6 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of the costs of Wuhan Miracle. Cost of revenues included share-based compensation expenses of RMB5.8 million (US$0.9 million) during the fourth quarter of 2021, compared with RMB5.0 million in the corresponding period of 2020.
Operating Expenses
Total operating expenses were RMB371.9 million (US$58.4 million), an increase of 12.3% from RMB331.2 million in the fourth quarter of 2020.
- Sales and marketing expenses were RMB152.7 million (US$24.0 million), a decrease of 27.4% from RMB210.4 million in the fourth quarter of 2020. The decrease was primarily due to a decrease in expenses associated with branding and marketing activities. Sales and marketing expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB3.7 million (US$0.6 million), compared with RMB2.2 million in the corresponding period of 2020.
- General and administrative expenses were RMB85.9 million (US$13.5 million), an increase of 72.1% from RMB49.9 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of Wuhan Miracle. General and administrative expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB32.3 million (US$5.1 million), compared with RMB11.3 million in the corresponding period of 2020.
- Research and development expenses were RMB67.5 million (US$10.6 million), a decrease of 4.8% from RMB70.9 million in the fourth quarter of 2020. The decrease was primarily due to the decrease of payroll costs. Research and development expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB7.1 million (US$1.1 million), compared with RMB5.9 million in the corresponding period of 2020.
- Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).
Income Tax Expenses
Income tax expenses were RMB10.1 million (US$1.6 million), compared with RMB13.0 million in the same period of 2020.
Net income/(loss) attributable to So-Young International Inc.
Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with a net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.
Non-GAAP net income attributable to So-Young International Inc.
Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB62.9 million (US$9.9 million), compared with RMB63.1 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2020.
Basic and Diluted Earnings/(Loss) per ADS
Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.26 (US$0.04) and RMB0.26 (US$0.04), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.36 and RMB0.35, respectively, in the same period of 2020.
Fiscal Year 2021 Financial Results
Revenues
Total revenues were RMB1,692.5 million (US$265.6 million), an increase of 30.7% from RMB1,295.0 million in fiscal year 2020.
- Information services and other revenues were RMB1,304.5 million (US$204.7 million), an increase of 35.6% from RMB962.1 million in fiscal year 2020. The increase was primarily attributable to an increase in average revenue per medical service provider.
- Reservation services revenues were RMB276.1 million (US$43.3 million), a decrease of 17.1% from RMB332.9 million in fiscal year 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.
- Sales of equipment and maintenance services revenues were RMB112.0 million (US$17.6 million), from Wuhan Miracle, our newly acquired subsidiary.
Cost of Revenues
Cost of revenues were RMB327.9 million (US$51.5 million), an increase of 54.5% from RMB212.2 million in fiscal year 2020. The increase was primarily due to the consolidation of Wuhan Miracle. In addition, cost of revenues for fiscal year 2021 included share-based compensation expenses of RMB18.8 million (US$2.9 million) compared to RMB18.3 million in fiscal year 2020.
Operating Expenses
Total operating expenses were RMB1,397.1 million (US$219.2 million), an increase of 22.6% from RMB1,139.5 million in fiscal year 2020.
- Sales and marketing expenses were RMB792.5 million (US$124.4 million), an increase of 9.1% from RMB726.3 million in fiscal year 2020. The increase was primarily due to an increase in expenses associated with marketing campaigns and user acquisition initiatives and the consolidation of Wuhan Miracle. Sales and marketing expenses for fiscal year 2021 included share-based compensation expenses of RMB9.8 million (US$1.5 million), compared to RMB6.7 million in fiscal year 2020.
- General and administrative expenses were RMB252.2 million (US$39.6 million), an increase of 37.1% from RMB184.0 million in fiscal year 2020. This was primarily due to an increase in personnel related expenses and the consolidation of Wuhan Miracle. General and administrative expenses for 2021 included share-based compensation expenses of RMB56.7 million (US$8.9 million), compared to RMB46.0 million in fiscal year 2020.
- Research and development expenses were RMB286.6 million (US$45.0 million), an increase of 25.0% from RMB229.2 million in fiscal year 2020. The increase was primarily attributable to an increase in personnel related expenses. Research and development expenses for 2021 included share-based compensation expenses of RMB20.9 million (US$3.3 million), compared to RMB21.1 million in fiscal year 2020.
- Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).
Income Tax (Expenses)/Benefit
Income tax expenses were RMB21.2 million (US$3.3 million), compared with an income tax benefit of RMB4.8 million in fiscal year 2020. The income tax benefit was derived from a change in the preferential income tax rate of one of So-Young’s subsidiaries, which resulted in a refund of RMB16.4 million for tax paid in previous periods.
Net income/(loss) attributable to So-Young International Inc.
Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million), compared with a net income attributable to So-Young International Inc. of RMB5.8 million in fiscal year 2020.
Non-GAAP net income attributable to So-Young International Inc.
Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB139.5 million (US$21.9 million), compared with RMB98.0 million non-GAAP net income attributable to So-Young International Inc. in fiscal year 2020.
Basic and Diluted Earnings per ADS
Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.08 (US$0.01) and RMB0.08 (US$0.01), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.05 and RMB0.05 in fiscal year 2020.
Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments
As of December 31, 2021, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,756.0 million (US$275.6 million), compared with RMB2,676.0 million as of December 31, 2020.
Business Outlook
For the first quarter of 2022, So-Young expects its total revenues to be between RMB290 million (US$46.0 million) and RMB300 million (US$47.0 million), representing a 19.4% to 16.6% decrease from the same period in 2021. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, and customer demand, particularly in view of the potential impact of the COVID-19, the effects of which are difficult to analyze and predict, which are all subject to changes.
Non-GAAP Financial Measures
To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and intangible assets from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. The impairment of goodwill and intangible assets are considered unusual charges as the company does not have frequent such charges. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses and impairment of goodwill and intangible assets in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.For more information, please contact:
So-Young
Investor Relations
Ms. Vivian Xu
Phone: +86-10-8790-2012
E-mail: ir@soyoung.comChristensen
In China
Mr. Eric Yuan
Phone: +86-10-5900-1548
E-mail: Eyuan@christensenir.comIn US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@christensenir.comSO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except for share and per share data) As of December 31,
2020December 31,
2021December 31,
2021RMB RMB US$ Assets Current assets: Cash and cash equivalents 1,127,055 1,331,968 209,015 Restricted cash and term deposits 21,865 15,119 2,373 Trade receivables 52,871 54,829 8,604 Inventories, net - 91,812 14,407 Receivables from online payment platforms 16,182 18,864 2,960 Amounts due from related parties 7,764 14,038 2,203 Term deposits and short-term investments 1,527,088 408,946 64,173 Prepayment and other current assets 43,190 91,842 14,412 Total current assets 2,796,015 2,027,418 318,147 Non-current assets: Long-term investments 166,100 252,500 39,623 Intangible assets 60,029 193,955 30,436 Goodwill 48,500 540,693 84,847 Property and equipment, net 29,830 124,576 19,549 Deferred tax assets 55,520 47,520 7,457 Operating lease right-of-use assets 120,140 95,609 15,003 Other non-current assets 15,878 48,097 7,547 Total non-current assets 495,997 1,302,950 204,462 Total assets 3,292,012 3,330,368 522,609 Liabilities Current liabilities: Taxes payable 60,070 48,571 7,622 Contract liabilities 135,385 139,155 21,836 Salary and welfare payables 95,758 103,624 16,261 Amounts due to related parties 2,404 681 107 Accrued expenses and other current liabilities 237,785 376,841 59,136 Operating lease liabilities-current 39,468 43,529 6,831 Total current liabilities 570,870 712,401 111,793 Non-current liabilities: Operating lease liabilities-non current 93,044 62,356 9,785 Deferred tax liabilities 8,522 38,577 6,054 Total non-current liabilities 101,566 100,933 15,839 Total liabilities 672,436 813,334 127,632 Mezzanine equity Redeemable non-controlling interests 23,205 - - Total mezzanine equity 23,205 - - SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued) (All amounts in thousands, except for share and per share data, unless otherwise noted) Shareholders’ equity: Treasury stock - (217,712 ) (34,164 ) Class A Ordinary shares (US$ 0.0005 par value; 750,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 70,212,159 shares issued and outstanding as of December 31, 2020; 71,736,059 and 69,092,367 shares issued and outstanding as of December 31, 2021, respectively) 224 230 36 Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 12,000,000 shares issued and outstanding as of December 31, 2020 and December 31, 2021) 37 37 6 Additional paid-in capital 2,892,268 2,999,562 470,697 Statutory reserves 10,562 20,331 3,190 Accumulated deficit (254,228 ) (272,368 ) (42,740 ) Accumulated other comprehensive loss (52,492 ) (83,891 ) (13,164 ) Total So-Young International Inc. shareholders’ equity 2,596,371 2,446,189 383,861 Non-controlling interests - 70,845 11,116 Total shareholders’ equity 2,596,371 2,517,034 394,977 Total liabilities, mezzanine equity and shareholders’ equity 3,292,012 3,330,368 522,609 SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except for share and per share data) For the Three Months Ended For the Fiscal Year Ended December 31,
2020December 31,
2021December 31,
2021December 31,
2020December 31,
2021December 31,
2021RMB RMB US$ RMB RMB US$ Revenues Information services and others 335,911 344,315 54,030 962,089 1,304,455 204,697 Reservation services 88,724 41,372 6,493 332,899 276,052 43,320 Sales of equipment and maintenance services - 63,836 10,017 - 111,956 17,568 Total revenues 424,635 449,523 70,540 1,294,988 1,692,463 265,585 Cost of revenues (63,620 ) (127,090 ) (19,943 ) (212,206 ) (327,889 ) (51,453 ) Gross profit 361,015 322,433 50,597 1,082,782 1,364,574 214,132 Operating expenses: Sales and marketing expenses (210,378 ) (152,656 ) (23,955 ) (726,297 ) (792,484 ) (124,358 ) General and administrative expenses (49,888 ) (85,852 ) (13,472 ) (183,987 ) (252,214 ) (39,578 ) Research and development expenses (70,920 ) (67,519 ) (10,595 ) (229,192 ) (286,567 ) (44,969 ) Impairment of goodwill and intangible assets - (65,879 ) (10,338 ) - (65,879 ) (10,338 ) Total operating expenses (331,186 ) (371,906 ) (58,360 ) (1,139,476 ) (1,397,144 ) (219,243 ) Income/(loss) from operations 29,829 (49,473 ) (7,763 ) (56,694 ) (32,570 ) (5,111 ) Other income/(expenses): Investment income 3,130 927 145 13,599 8,931 1,401 Interest income 6,753 3,654 573 39,669 19,328 3,033 Exchange (losses)/gain (603 ) 33 5 (1,118 ) (4,766 ) (748 ) Impairment of long-term investment - - - - (17,850 ) (2,801 ) Share of gain/(losses) of equity method investee 198 (746 ) (117 ) (4,279 ) (1,522 ) (239 ) Others, net 11,407 2,208 346 8,916 12,044 1,890 Income/(loss) before tax 50,714 (43,397 ) (6,811 ) 93 (16,405 ) (2,575 ) Income tax (expenses)/benefit (12,997 ) (10,145 ) (1,592 ) 4,784 (21,231 ) (3,332 ) Net income/(loss) 37,717 (53,542 ) (8,403 ) 4,877 (37,636 ) (5,907 ) Net loss attributable to noncontrolling interests 930 25,806 4,050 930 29,265 4,592 Net income/(loss) attributable to So-Young International Inc. 38,647 (27,736 ) (4,353 ) 5,807 (8,371 ) (1,315 ) SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued) (Amounts in thousands, except for share and per share data) For the Three Months Ended For the Fiscal Year Ended December 31, 2020 December 31, 2021 December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2021 RMB RMB US$ RMB RMB US$ Net income/(loss) per ordinary share Net earnings/(loss) per ordinary share attributable to ordinary shareholder - basic 0.47 (0.34 ) (0.05 ) 0.07 (0.10 ) (0.02 ) Net earnings/(loss) per ordinary share attributable to ordinary shareholder - diluted 0.46 (0.34 ) (0.05 ) 0.07 (0.10 ) (0.02 ) Net earnings/(loss) per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares) 0.36 (0.26 ) (0.04 ) 0.05 (0.08 ) (0.01 ) Net earnings/(loss) per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares) 0.35 (0.26 ) (0.04 ) 0.05 (0.08 ) (0.01 ) Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic* 81,904,047 81,304,182 81,304,182 81,534,991 81,680,504 81,680,504 Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted* 84,108,250 81,304,182 81,304,182 83,781,406 81,680,504 81,680,504 Share-based compensation expenses included in: Cost of revenues (5,040 ) (5,830 ) (915 ) (18,327 ) (18,768 ) (2,945 ) Sales and marketing expenses (2,183 ) (3,719 ) (584 ) (6,711 ) (9,808 ) (1,539 ) General and administrative expenses (11,311 ) (32,259 ) (5,062 ) (46,001 ) (56,705 ) (8,898 ) Research and development expenses (5,943 ) (7,106 ) (1,115 ) (21,131 ) (20,869 ) (3,275 ) * Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.
SO-YOUNG INTERNATIONAL INC. Reconciliation of GAAP and Non-GAAP Results (Amounts in thousands, except for share and per share data) For the Three Months Ended For the Fiscal Year Ended December 31, 2020 December 31, 2021 December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2021 RMB RMB US$ RMB RMB US$ GAAP income/(loss) from operations 29,829 (49,473 ) (7,763 ) (56,694 ) (32,570 ) (5,111 ) Add back: Shared-based compensation expenses 24,477 48,914 7,676 92,170 106,150 16,657 Add back: Impairment of goodwill and intangible assets - 65,879 10,338 - 65,879 10,338 Non-GAAP income from operations 54,306 65,320 10,251 35,476 139,459 21,884 GAAP Net income/(loss) attributable to So-Young International Inc. 38,647 (27,736 ) (4,353 ) 5,807 (8,371 ) (1,315 ) Add back: Shared-based compensation expenses 24,477 48,914 7,676 92,170 106,150 16,657 Add back: Impairment of goodwill and intangible assets attributable to So-Young International Inc. - 41,748 6,551 - 41,748 6,551 Non-GAAP Net income attributable to So-Young International Inc. 63,124 62,926 9,874 97,977 139,527 21,893 _________________________
1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.3726 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 30, 2021.
2 Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.
- Total revenues were RMB449.5 million (US$70.5 million1), an increase of 5.9% from RMB424.6 million in the same period of 2020, in line with our previous guidance.